| Name | Casein Kinase II Inhibitor IV |
| Description | Casein Kinase II Inhibitor IV is an inducer of epidermal keratinocyte differentiation. |
| In vitro | Treatment with Casein Kinase II Inhibitor IV on human epidermal keratinocytes (NHEKs) enhances early differentiation markers, keratins 1 and 10, at 48 hours, while increasing levels of IVL and TGM at 72 hours, sustained through 96 hours. This inhibitor also prompts the expression of loricrin, a terminal differentiation marker, at subsequent time points. Correspondingly, mRNA expression analysis confirms upregulation of early differentiation marker genes, specifically keratin 1 and keratin 10 by 5.4-fold at 12 and 24 hours. Late-differentiation marker genes, including IVL (1.8-fold), TGM 1 (4.8-fold), loricrin (3.3-fold), and filaggrin (5.6-fold), exhibit increased expression at 36 and 48 hours in NHEKs treated with Casein Kinase II Inhibitor IV. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 70 mg/mL (162.99 mM), Sonication is recommended.
|
| Keywords | Inhibitor | Casein Kinase | inhibit | Casein Kinase II Inhibitor IV |
| Inhibitors Related | TBCA | CK2-IN-4 | Ellagic acid | Silmitasertib | CK2α-IN-1 | Emodin | LY-364947 | AS-252424 | TA-01 | CK2/ERK8-IN-1 | Casein kinase 1δ-IN-6 | LY294002 |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | Bioactive Compounds Library Max |
United States
